Connecting to Purpose: Remembering Mom During Alzheimer’s Awareness Month

By Karen Hagens, VP Global Corporate Communications,

The last time I saw my mom alive, I helped her eat dinner while my son colored her a picture. We were outside, due to Covid-19 restrictions. We were lucky to finally see her in person after almost a year of daily FaceTime videos, and window visits. Of course, none of us knew it would be our last visit. She died on April 3, 2021. My mom was one of the six million Americans living with Alzheimer’s Disease. According to the Alzheimer’s Foundation, this number is projected to more than double to nearly 13 million by 2050. To those caring for someone with Alzheimer’s, death isn’t the enemy in the end. It’s the decline, whether fast or slow, and the fading away of your loved one before your very eyes that eats away at your soul. Alzheimer’s is the cruelest of diseases. It’s for people like my mom that I do what I do. I am not a scientist. I will never find the cure for Alzheimer’s. But, as a communicator, I chose to specialize in healthcare communications almost 20 years ago over other industries like fashion, travel, or manufacturing, so that I could contribute in some small way to the pursuit of science. I recently joined Worldwide Clinical Trials, where I surround myself with front-line scientific and therapeutic experts...

Read More

Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

Old people with neurodegenerative diseases
By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 3 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

In a major departure, the new Alzheimer’s disease (AD) research framework by the National Institutes on Aging and Alzheimer’s Association (NIA-AA) separates clinical symptoms from pathological state (1). This shift in thinking away from AD as a clinical-pathological construct and then as a clinical-biomarker construct (where biomarkers were used to support an AD diagnosis) represents the key feature to the updated research framework released in 2017 (2). 

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 2 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  The common Alzheimer’s disease research framework proposed in 2017 by the National Institute on Aging and Alzheimer’s Association (NIA-AA) pivots upon the understanding and acknowledgment that Alzheimer’s disease (AD) refers to an aggregate of pathophysiologic processes and therefore can be uniquely defined in vivo by biomarkers and, of course, by post mortem pathologic changes but conspicuously not by clinical symptomatology (1, 2).

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 1 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  In 2017, the National Institute of Aging and Alzheimer’s Association (NIA-AA) proposed a common research framework to help clinical investigators establish a research agenda and evaluate the impact of various therapeutics in the Alzheimer’s disease (AD) continuum, and specifically to define and stage AD and facilitate research reporting. 

Read More